Skip to main content

Table 1 Characteristics of 18 subjects under the study and microbiological details of 35 isolated Malassezia species

From: Distribution of Malassezia species on the skin of patients with atopic dermatitis, psoriasis, and healthy volunteers assessed by conventional and molecular identification methods

 

Patienta

Subject groupb

Collection site

Sexc

Age

Lesion severityd

Episodee

Duration of disease [yrs]

Treatmentf

Family history of disease

Other diseasesg

Strain no.

Species identifictionh

1.

TK

AD

Head

M

24

37

R

24

Topical; sys: antihistaminics

Positive

No

40.10.I.

M. sympodialis

2.

Face

40.10.II.

M. sympodialis

3.

Back

40.10.IV.

M. sympodialis

4.

MP

Head

F

28

31

R

23

Topical; sys: antihistaminics

Positive

Rhinoconjunctivitis

8.11.I.

M. sympodialis

5.

Chest

8.11.III.

M. sympodialis + C. d. *

6.

Back

8.11.IV.

M. sympodialis

7.

DJ

Chest

M

29

34.6

R

29

Topical; sys: antihistaminics

Positive

Rhinoconjunctivitis

27.10.III.

M. sympodialis

8.

Back

27.10.IV.

M. sympodialis

9.

JW

Chest

F

22

10.2

R

22

Topical; sys: antihistaminics

Positive

No

7.11.III.

M. sympodialis

10.

Back

7.11.IV.

M. sympodialis

11.

MB

Back

M

22

39.4

R

22

Topical; sys: antihistaminics

Negative

 

25.10.IV.

M. sympodialis

12.

EP

Back

F

31

10.2

R

31

Topical; sys: antihistaminics

Negative

Vitiligo

17.10.IV.

M. sympodialis

13.

BT

PS

Head

F

50

8.2

R

20

Topical; sys: CyA

Positive

No

10.11.I.

M. sympodialis

14.

Face

10.11.II.

M. sympodialis + A. p. **

15.

Chest

10.11.IIIA.

M. furfur

16.

Back

10.11.IV.

M. sympodialis

17.

BH

Face

F

44

10

R

15

Topical

Negative

No

45.08.II.

M. furfur

18.

Chest

45.08.III.

M. furfur + M. sympodialis

19.

SK

Back

M

38

3.6

R

5

Topical; sys: CS

Negative

No

20.09.IV.

M. furfur + M. sympodialis

20.

EN

Back

F

31

6.6

R

5

Topical

Negative

No

17.09.IV.

M. sympodialis

21.

KK

Face

M

23

11.2

R

12

Topical; sys: CyA

Positive

No

43.08.II.

M. furfur

22.

MB

Back

F

29

5.7

R

15

Topical

Positive

No

6.11.IV.

M. sympodialis

23.

MT

Control

Head

F

31

     

No

1.11.IA.

M. globosa

24.

Face

1.11.II.

M. globosa + M. restricta

25.

Chest

1.11.IIIA.

M. sympodialis

26.

Back

1.11.IVA.

M. sympodialis

27.

CM

Chest

M

70

     

No

69.09.III.

M. slooffiae

28.

Back

69.09.IV.

M. slooffiae + M. sympodialis

29.

BP

Chest

M

69

     

No

67.09.III.

M. sympodialis

30.

Back

67.09.IV.

M. sympodialis

31.

PK

Chest

M

27

     

No

68.09.III.

M. sympodialis

32.

Back

68.09.IV.

M. sympodialis

33.

MS

Chest

F

28

     

No

2.11.III.

M. sympodialis

34.

Back

2.11.IV.

M. sympodialis

35.

JP

Back

F

31

     

No

12.09.IV.

M. sympodialis

  1. aPatient initials.
  2. bThree subject groups under investigation: (i) patients with atopic dermatitis (AD), (ii) patients with psoriasis (PS), and (iii) healthy volunteers (control).
  3. cM, male; F, female.
  4. dThe numbers represent the SCORAD index values in AD patients, or the PASI index values in psoriatic patients.
  5. eR, recurrent.
  6. fTopic treatment for AD patients included emolients, corticosteroids, tacrolimus, pimecrolimus, antibiotics, whereas topic treatment for psoriatic patients included corticosteroids, calcipotriol, tacrolimus, pimecrolimus, emollients; CS, corticosteroids; CyA: Cyclosporine A; sys., systemic.
  7. gBased on direct interviewing of the patients.
  8. hFinal species identification results, based upon integration of conventional and molecular data. * C. d., Cryptococcus diffluens; ** A. p., Aureobasidium pullulans.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us